Skip to main content
Premium Trial:

Request an Annual Quote

Edico Genome, Amazon Web Services Partner on Cloud Bioinformatics

NEW YORK (GenomeWeb) – Edico Genome said today that it is partnering with Amazon Web Services to make Edico's Dragen bioinformatics platform available on new Amazon cloud-based instances.

"With AWS' newest [Field Programmable Gate Array]-based instances, Dragen will be able to analyze whole genomes in almost real time," Edico CEO Pieter van Rooyen said in a statement.

The Dragen platform offers hardware-accelerated implementation of genomic analysis algorithms, reducing analysis time. Specifically, Edico will be deploying it on the Amazon Elastic Compute Cloud (EC2) F1 instances.

It's yet another computing resource that Edico has integrated Dragen into. The firm has a deal with Intel to integrate the Dragen platform with Intel processors, and in May Edico announced a partnership with IBM to make Dragen available on one of IBM's high-performance computing servers.

The firm said that adding a cloud configuration provides customers the flexibility to scale up analysis when on-site resources are in high demand. "Pipelines are identical whether executed in the cloud or on-site," the firm said in a statement, adding that both systems can be managed using the Dragen web portal.

Pricing for the Dragen cloud solution has not yet been determined but will be announced by the end of 2016, Edico said.

"We look forward to offering a secure, highly scalable, and cost-efficient platform for genomic analysis to Edico customers, hospitals, academic institutions, drug developers, sequencing centers, and others advancing genomic-based work," van Rooyen said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.